Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Post by TawiTwaion Jun 19, 2024 2:40am
265 Views
Post# 36095390

V.SBM - What do I expect to happen next?

V.SBM - What do I expect to happen next?

What do I expect to happen next ? 
 
In a few days, when Stonegate’s investors and subscribers had time to review the report, I am certain they will want to get on the phone and pitch Sirona Biochem. Probably, they will line up a couple of meetings with Stonegate, who will explain the significance of GlycoProteMim compared to what is currently out there. It is nice to have someone with a real Biotech background explain the technology and products, rather than Howard or Geraldine that most people have a hard time understanding or relating to. 
 
In any case, there should be plenty of US investors who will pick up a position in the public market, the stock is a steal right now. In regards to mid-size and larger institutional investors, I assume that there could be different financing models. Either a debt deal or private equity into Sirona Laboratories plus some money for Sirona Biochem, to get GlycoProteMim launched as soon as possible. 
 
I also like the fact that they are targeting the US for the first time, to attract fresh investors who are not depleted like the existing investors. Further, I assume that Stonegate would take over the business development, a crucial part that has been neglected, due to the time restraints of the current management. 
 
I also anticipate that Stonegate will launch additional updates and maybe a more detailed report on Sirona Biochem, evaluating their entire intellectual property line and financials. In any case, this was a smart move to start with GlycoProteMim, rather than trying to push the stock, a solid approach in my opinion. 

Some additional things....

- A brief video from Shiv Kapoor  presenting the technology and the business verticals would be nice.

- I am certain that Indie Bio and SOSV investment firms are currently looking at Sirona Biochem, as they were key investors into OneSkins technology. 

- Does anyone know if there is a french version of the stonegate report ?

<< Previous
Bullboard Posts
Next >>